Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTNM NASDAQ:GALT NASDAQ:IMRX NASDAQ:OCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTNMContineum Therapeutics$11.88-4.1%$7.65$3.35▼$20.30$333.12M1.13148,618 shs149,855 shsGALTGalectin Therapeutics$4.41-2.0%$3.72$0.73▼$6.55$282.51M0.86407,373 shs383,090 shsIMRXImmuneering$8.31+5.7%$4.65$1.10▼$9.37$345.45M0.431.24 million shs593,580 shsOCXOncoCyte$3.18+16.3%$3.07$1.92▼$4.75$90.80M0.9758,260 shs100,514 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTNMContineum Therapeutics+0.32%+2.14%+67.89%+215.27%-35.37%GALTGalectin Therapeutics-16.20%-3.64%+26.05%+88.28%+56.79%IMRXImmuneering-7.42%+32.10%+109.04%+331.87%+289.11%OCXOncoCyte0.00%0.00%0.00%-0.78%+3.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTNMContineum Therapeutics$11.88-4.1%$7.65$3.35▼$20.30$333.12M1.13148,618 shs149,855 shsGALTGalectin Therapeutics$4.41-2.0%$3.72$0.73▼$6.55$282.51M0.86407,373 shs383,090 shsIMRXImmuneering$8.31+5.7%$4.65$1.10▼$9.37$345.45M0.431.24 million shs593,580 shsOCXOncoCyte$3.18+16.3%$3.07$1.92▼$4.75$90.80M0.9758,260 shs100,514 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTNMContineum Therapeutics+0.32%+2.14%+67.89%+215.27%-35.37%GALTGalectin Therapeutics-16.20%-3.64%+26.05%+88.28%+56.79%IMRXImmuneering-7.42%+32.10%+109.04%+331.87%+289.11%OCXOncoCyte0.00%0.00%0.00%-0.78%+3.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTNMContineum Therapeutics 3.17Buy$22.7591.10% UpsideGALTGalectin Therapeutics 3.00Buy$6.0035.90% UpsideIMRXImmuneering 2.60Moderate Buy$13.7565.48% UpsideOCXOncoCyte 2.75Moderate Buy$6.0690.94% UpsideCurrent Analyst Ratings BreakdownLatest OCX, IMRX, CTNM, and GALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $11.008/26/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.008/18/2025CTNMContineum TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $21.008/14/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.008/14/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.006/20/2025CTNMContineum TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform6/18/2025IMRXImmuneeringMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $10.006/18/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.006/18/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.006/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTNMContineum Therapeutics$50M6.68N/AN/A$7.66 per share1.55GALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/AIMRXImmuneering$320K1,079.39N/AN/A$1.33 per share6.25OCXOncoCyte$3.84M23.63N/AN/A($0.70) per share-4.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTNMContineum Therapeutics-$42.26M-$2.20N/AN/AN/AN/A-29.75%-28.08%11/5/2025 (Estimated)GALTGalectin Therapeutics-$47.05M-$0.64N/AN/AN/AN/AN/A-225.32%11/13/2025 (Estimated)IMRXImmuneering-$61.04M-$1.89N/AN/AN/AN/A-146.28%-117.22%11/12/2025 (Estimated)OCXOncoCyte-$60.66M-$3.53N/AN/AN/A-1,516.06%-215.59%-27.23%N/ALatest OCX, IMRX, CTNM, and GALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025GALTGalectin Therapeutics-$0.16-$0.12+$0.04-$0.12N/AN/A8/13/2025Q2 2025IMRXImmuneering-$0.40-$0.40N/A-$0.40N/AN/A8/5/2025Q2 2025CTNMContineum Therapeutics-$0.56-$0.62-$0.06-$0.62$7.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTNMContineum TherapeuticsN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/AOCXOncoCyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTNMContineum TherapeuticsN/A24.5124.51GALTGalectin TherapeuticsN/A1.431.43IMRXImmuneeringN/A3.703.70OCXOncoCyte0.203.743.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTNMContineum TherapeuticsN/AGALTGalectin Therapeutics11.68%IMRXImmuneering67.65%OCXOncoCyte55.35%Insider OwnershipCompanyInsider OwnershipCTNMContineum Therapeutics11.30%GALTGalectin Therapeutics50.10%IMRXImmuneering22.90%OCXOncoCyte2.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTNMContineum Therapeutics3128.04 million24.87 millionN/AGALTGalectin Therapeutics964.06 million31.97 millionOptionableIMRXImmuneering6041.57 million32.05 millionNot OptionableOCXOncoCyte12028.60 million28.01 millionNo DataOCX, IMRX, CTNM, and GALT HeadlinesRecent News About These CompaniesOncocyte Exits Irvine, Rebrands as Insight Molecular DiagnosticsJune 18, 2025 | ocbj.comOOncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to NashvilleJune 17, 2025 | globenewswire.comOncocyte Corp. Adjusts Pricing for GraftAssureCore™ Assay to $2,753, Enhancing Market Opportunities and Reimbursement PotentialMay 21, 2025 | nasdaq.comOncocyte Corporation: Medicare Boosts Reimbursement for Oncocyte's Flagship TechnologyMay 20, 2025 | finanznachrichten.deMedicare Boosts Reimbursement for Oncocyte’s Flagship TechnologyMay 19, 2025 | finance.yahoo.comMedicare Boosts Reimbursement for Oncocyte's Flagship TechnologyMay 19, 2025 | globenewswire.comOncocyte Corporation: Oncocyte Reports Q1 2025 Results and Business ProgressMay 13, 2025 | finanznachrichten.deOncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiativeMay 13, 2025 | msn.comOncoCyte Corporation (OCX) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comOncocyte Reports Q1 2025 Results and Business ProgressMay 12, 2025 | globenewswire.comOncoCyte Q1 2025 Earnings PreviewMay 11, 2025 | msn.comOncocyte to Release First Quarter 2025 Results on May 12, 2025May 7, 2025 | globenewswire.comOncocyte to Release First Quarter 2025 Results on May 12, 2025May 7, 2025 | prismmediawire.comPWhy OncoCyte Corporation’s (OCX) Stock Is Up 5.11%May 7, 2025 | aaii.comABest Momentum Stocks to Buy for May 6thMay 6, 2025 | zacks.comNew Strong Buy Stocks for May 6thMay 6, 2025 | zacks.comOncocyte Corporation: Oncocyte Provides Positive Update on Clinical Trial ProgressApril 30, 2025 | finanznachrichten.deOncocyte study links blood test to kidney rejection markersApril 30, 2025 | investing.comOncocyte Provides Positive Update on Clinical Trial ProgressApril 30, 2025 | globenewswire.comOncocyte’s Proprietary Assay Demonstrates Long-Term Clinical ValidityApril 29, 2025 | taiwannews.com.twTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCX, IMRX, CTNM, and GALT Company DescriptionsContineum Therapeutics NASDAQ:CTNM$11.88 -0.51 (-4.12%) Closing price 04:00 PM EasternExtended Trading$11.87 -0.01 (-0.08%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Galectin Therapeutics NASDAQ:GALT$4.41 -0.09 (-2.00%) Closing price 04:00 PM EasternExtended Trading$4.42 +0.01 (+0.14%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Immuneering NASDAQ:IMRX$8.31 +0.45 (+5.73%) Closing price 04:00 PM EasternExtended Trading$8.48 +0.16 (+1.99%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.OncoCyte NASDAQ:OCXOncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
